Construction of a bispecific single-chain antibody derivative is described that consists of two
different single-chain Fv fragments joined through a Gly-Ser linker. One specificity of the two …

For an antibody to be an effective therapeutic agent, it must work in concert with the human
complement system and/or with cytotoxic trigger molecules on killer (effector) cells. In …

We now know that tumor necrosis factor (TNF) family ligands regulate development of
lymphoid tissue and coordinate cellular differentiation to defend against intracellular …

Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting
preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal …

CD8+ CTL are the main effector cells responsible for resolving viral infections. However, the
CTL response to respiratory syncytial virus (RSV) infection in mice facilitates viral clearance …

Relapse after adjuvant chemotherapy or high-dose chemotherapy with stem cell transplant
for high-risk breast cancer remains high and new strategies that provide additional antitumor …

Novel Ab-based immunotherapeutic strategies have exploited T-cell receptor-like chimeric
immune receptors (CIR) expressed on the surface of transduced human peripheral blood …

Introduction Prostate cancer is the second most common cancer in men worldwide. When
the disease becomes resistant to androgen-deprivation therapy, treatment options are …

The bispecific antibody (BiAb) anti-CD3× anti-Her2/neu (Her2Bi), combines Her2/neu
targeting with nonmajor histocompatibility complex–restricted cytotoxicity mediated by …

Many strategies for experimental immunotherapy of cancers aim at inducing and expanding
tumor-specific cytotoxic T-lymphocytes. One of the most promising approaches uses …